Key result
Sacubitril-valsartan resulted in a mean of 1 to 2 additional years of survival compared with enalapril in patients with heart failure.
Why the study?
Does sacubitril-valsartan improve survival in patients with heart failure compared with enalapril?
Does sacubitril-valsartan improve survival in patients with heart failure compared with enalapril?
Actuarial modeling of PARADIGM-HF data suggests sacubitril-valsartan provides an estimated 1 to 2 additional years of survival compared to enalapril in heart failure patients.
Offers survival projections to aid HF counseling; leaves open real-world validation beyond trial modeling.
Using actuarial data based on the results of the PARADIGM-HF trial, investigators found that the use of sacubitril–valsartan in patients with heart failure resulted in a mean of 1 to 2 additional years of survival, as compared with enalapril.
No takes yet. Share an insight, caveat, or question.
Claggett et al. (2015) studied this question. Sacubitril-valsartan resulted in a mean of 1 to 2 additional years of survival compared with enalapril in patients with heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: